AbbVie, the partner company of the Hungarian pharmaceutical firm Gedeon Richter Plc., has submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR®) to the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. The submission is supported by results from […]
Gedeon Richter Plc. has announced that it extended its existing licensing agreement with AbbVie, originally dated 2004, for the development and commercialization of its own-developed molecule, cariprazine. The initial agreement covered the territories of the USA and Canada and was extended in 2019 to include certain countries in Latin America. The present agreement further expands […]
